Fiera Capital Corp lowered its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 23.2% in the 2nd quarter, according to the company in its most recent filing with the SEC. The firm owned 46,775 shares of the biopharmaceutical company’s stock after selling 14,105 shares during the quarter. Fiera Capital Corp’s holdings in Gilead Sciences were worth $3,310,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its holdings in shares of Gilead Sciences by 1.0% in the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock worth $2,185,784,000 after acquiring an additional 310,607 shares during the period. Franklin Resources Inc. lifted its position in shares of Gilead Sciences by 1.0% in the second quarter. Franklin Resources Inc. now owns 14,516,058 shares of the biopharmaceutical company’s stock valued at $1,027,436,000 after acquiring an additional 136,884 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Gilead Sciences by 9.3% in the second quarter. Legal & General Group Plc now owns 7,004,455 shares of the biopharmaceutical company’s stock valued at $495,778,000 after acquiring an additional 596,992 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Gilead Sciences by 25.7% in the first quarter. AQR Capital Management LLC now owns 5,213,046 shares of the biopharmaceutical company’s stock valued at $354,070,000 after acquiring an additional 1,066,172 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of Gilead Sciences by 2.3% in the second quarter. Swiss National Bank now owns 4,775,524 shares of the biopharmaceutical company’s stock valued at $338,012,000 after acquiring an additional 107,400 shares in the last quarter. Institutional investors own 76.23% of the company’s stock.
In other news, insider John C. Martin sold 73,333 shares of the firm’s stock in a transaction that occurred on Monday, October 2nd. The shares were sold at an average price of $82.56, for a total transaction of $6,054,372.48. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Robin L. Washington sold 51,820 shares of the firm’s stock in a transaction that occurred on Thursday, September 7th. The stock was sold at an average price of $85.00, for a total transaction of $4,404,700.00. Following the sale, the chief financial officer now owns 43,352 shares of the company’s stock, valued at approximately $3,684,920. The disclosure for this sale can be found here. Insiders sold a total of 458,486 shares of company stock worth $35,190,731 over the last ninety days. 1.30% of the stock is currently owned by corporate insiders.
Gilead Sciences, Inc. (NASDAQ:GILD) traded down $2.25 during trading hours on Monday, hitting $73.09. The stock had a trading volume of 8,615,060 shares, compared to its average volume of 9,232,708. Gilead Sciences, Inc. has a 52-week low of $63.76 and a 52-week high of $86.27. The company has a debt-to-equity ratio of 1.10, a current ratio of 3.68 and a quick ratio of 3.56. The firm has a market cap of $95,450.00, a PE ratio of 7.86, a PEG ratio of -1.26 and a beta of 1.13.
Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating the Zacks’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion for the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s quarterly revenue was down 13.2% on a year-over-year basis. During the same period last year, the firm earned $2.75 EPS. equities research analysts expect that Gilead Sciences, Inc. will post 8.53 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Thursday, December 28th. Investors of record on Friday, December 15th will be paid a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.85%. The ex-dividend date of this dividend is Thursday, December 14th. Gilead Sciences’s dividend payout ratio is presently 23.66%.
Several brokerages have recently issued reports on GILD. Maxim Group raised Gilead Sciences from a “hold” rating to a “buy” rating and lifted their target price for the stock from $73.67 to $94.00 in a report on Thursday. Argus cut Gilead Sciences from a “buy” rating to a “hold” rating and lifted their target price for the stock from $73.25 to $73.77 in a report on Monday, November 13th. Mizuho boosted their price objective on Gilead Sciences from $77.00 to $83.00 and gave the stock a “buy” rating in a research note on Wednesday, November 8th. BMO Capital Markets reduced their price objective on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating on the stock in a research note on Friday, October 27th. Finally, J P Morgan Chase & Co set a $85.00 target price on Gilead Sciences and gave the company a “buy” rating in a research note on Wednesday, October 25th. One equities research analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average target price of $85.22.
WARNING: This article was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and reposted in violation of U.S. and international trademark & copyright legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2017/12/04/gilead-sciences-inc-gild-holdings-lowered-by-fiera-capital-corp.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.